GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » PB Ratio

ORKA (Oruka Therapeutics) PB Ratio : (As of Mar. 28, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-28), Oruka Therapeutics's share price is $12.50. Oruka Therapeutics's Book Value per Share for the fiscal year that ended in Dec. 2024 was $0.00. Hence, Oruka Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Oruka Therapeutics's PB Ratio or its related term are showing as below:

ORKA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.385
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Oruka Therapeutics PB Ratio Historical Data

The historical data trend for Oruka Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics PB Ratio Chart

Oruka Therapeutics Annual Data
Trend Dec24
PB Ratio
-

Oruka Therapeutics Semi-Annual Data
Mar24
PB Ratio -

Competitive Comparison of Oruka Therapeutics's PB Ratio

For the Biotechnology subindustry, Oruka Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's PB Ratio falls into.


;
;

Oruka Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Oruka Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (A: Dec. 2024)
=12.50/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Oruka Therapeutics  (NAS:ORKA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Oruka Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.